Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid Digestion01:06

Lipid Digestion

73.4K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
73.4K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Yearly attained adherence to Mediterranean diet, estimated trajectories of lipid profile from 60 to 80 years, and onset of clinical dyslipidemias in older adults at high cardiovascular risk.

Lipids in health and disease·2026
Same author

Effect of Dapagliflozin on Myocardial Fibrosis After STEMI: A Double-Blind, Placebo-Controlled Randomized Trial.

Journal of clinical medicine·2026
Same author

Metabolomic profiling in phenylketonuria: a systematic review of human studies.

Metabolomics : Official journal of the Metabolomic Society·2026
Same author

The influence of ethnicity and sex on lipid profile and cardiovascular risk factors: a population-based study.

Lipids in health and disease·2026
Same author

Brain MRI Radiomic First-Order Features for Presurgical Prediction of Meningioma Grading.

Journal of neuroimaging : official journal of the American Society of Neuroimaging·2026
Same author

SEA 2026 Standards for Global Control of Vascular Risk.

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis·2026
Same journal

The Mediterranean diet is about much more than just food: how, with whom and when you eat are just as important for your health as what and how much you eat.

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis·2026
Same journal

Cardiovascular risk and metabolomic profile in adolescents: A comparative study between anorexia nervosa, normal weight, and obesity.

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis·2026
Same journal

Lipid profile and angiogenic markers in the detection of preeclampsia: The RECLAMA study.

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis·2026
Same journal

LDL cholesterol control in patients with atherosclerotic carotid stenosis>50%, previous endarterectomy or carotid stent.

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis·2026
Same journal

Lipid lowering therapy in Tangier disease: what is the best association?

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis·2026
Same journal

Inclisiran for LDL-C reduction in secondary prevention: Real-world evidence from a homogeneous Spanish cohort with subgroup insights.

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.1K

Pilot study evaluating a clinical decision support tool: "Virtual Lipidologist HTE-DLP 3.0".

Alberto Zamora1, Cristina Soler2, Emilio Ortega3

  • 1Unidad de Lípidos y Riesgo Vascular, Servicio de Medicina Interna, Hospital Comarcal de Blanes, Blanes, Girona, España; Grupo de Innovación en Salud Digital-CSMS, Instituto de Investigación Biomédica de Girona Dr. Josep Trueta (CREA-IDIBGI), Girona, España; Facultad de Medicina, Universidad de Girona, Girona, España; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, España; Associació Xarxa d'Unitats de Lípids i Arterioesclerosi de Catalunya, Sociedad Catalana de Lípidos y Arteriosclerosis (SOC XULA), Barcelona, España.

Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis
|February 5, 2026
PubMed
Summary
This summary is machine-generated.

The HTE-DLP 3.0 (Virtual Lipidologist) significantly reduced therapeutic variability among clinicians, improving adherence to clinical guidelines. Further real-world studies are needed to confirm its clinical and cost-effectiveness.

Keywords:
Clinical decisión support systemsClinical variabilityDislipidemiaDyslipidemiaLipid-lowering therapySistemas de ayuda en la decisión clínicaTerapia hipolipidemianteVariabilidad clínica

More Related Videos

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.3K
Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
06:03

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

6.0K

Related Experiment Videos

Last Updated: May 1, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.1K
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.3K
Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
06:03

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

6.0K

Area of Science:

  • Medical Informatics
  • Clinical Decision Support Systems

Background:

  • Clinical decision support systems (CDSS) enhance guideline adherence and reduce practice variability.
  • HTE-DLP 3.0 (Virtual Lipidologist) offers evidence-based, safe, and cost-effective recommendations.

Purpose of the Study:

  • To evaluate the impact of HTE-DLP 3.0 on therapeutic variability and clinician decision-making.
  • To assess the usability and user experience of the HTE-DLP 3.0 system.

Main Methods:

  • A proof-of-concept study involved 9 clinicians evaluating 10 standardized cases before and after HTE-DLP 3.0 use.
  • Therapeutic variability was quantified using the Simpson Diversity Index and kappa coefficient.
  • Usability and user experience were assessed via CSUQ, QoE questionnaires, and a qualitative survey.

Main Results:

  • Baseline analysis revealed significant interprofessional variability, which was reduced to uniform adherence post-HTE-DLP 3.0 implementation.
  • The CSUQ indicated good efficiency (6.40) and high satisfaction (5.42/7), with suggestions for improving error messages and support tools.
  • QoE scores were high for data security (4.71), clinical usefulness (4.57), and social impact (4.57); learning time received the lowest score (2.85/5).

Conclusions:

  • HTE-DLP 3.0 effectively standardized clinical decisions according to practice guidelines.
  • Further real-world clinical practice studies are required to determine its clinical and cost-effectiveness.